Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605)
- PMID: 1808614
- DOI: 10.1023/a:1015842316177
Simultaneous modeling of the pharmacokinetics and methemoglobin pharmacodynamics of an 8-aminoquinoline candidate antimalarial (WR 238605)
Abstract
Methemoglobin (MHb) formation can be a clinically significant and dose-limiting side effect of 8-aminoquinoline antimalarials. MHb may also protect against cyanide poisoning. A two-compartment pharmacokinetic model, linked to a sigmoid Emax pharmacodynamic model, was developed to predict the MHb levels after administration of 8-[(4-amino-1-methylbutyl)amino]-2,6-dimethoxy-4-methyl-5-[(3- trifluoromethyl)phenoxy] quinoline succinate (WR 238605 succinate), a primaquine analogue. Six healthy male beagle dogs received four daily doses of 6.0 mg/kg (base) orally. Forty plasma drug concentrations and 19 MHb levels (effect) were determined over 7 weeks on each dog. Compartmental and noncompartmental pharmacokinetic and parametric and nonparametric pharmacodynamic analyses were performed. Model parameters (mean +/- SD) included a Vss/f of 18.5 +/- 2.8 L/kg, CL/f of 83 +/- 24 ml/hr/kg, terminal elimination t1/2 of 169.7 +/- 52.0 hr, t1/2keo of 123.0 +/- 22.4 hr, an Emax of 31.3 +/- 15.9% MHb, an EC50 of 596 +/- 128 ng/ml, and a sigmoidicity coefficient (n) of 1.94 +/- 0.47. The model was then validated in three additional dogs given three different dosing regimens. It predicted the peak plasma concentrations and MHb levels and the times of their occurrence well. This model could be useful for dose and sampling time selection in further animal studies and initial human phase I clinical testing.
Similar articles
-
Methemoglobin formation resulting from administration of candidate 8-aminoquinoline antiparasitic drugs in the dog.Fundam Appl Toxicol. 1988 Feb;10(2):270-5. doi: 10.1016/0272-0590(88)90311-9. Fundam Appl Toxicol. 1988. PMID: 3356313
-
Pharmacokinetics and kinetic-dynamic modeling of an 8-aminoquinoline candidate anticyanide and antimalarial drug (WR242511).Drug Metab Dispos. 1994 May-Jun;22(3):358-66. Drug Metab Dispos. 1994. PMID: 8070311
-
First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial.Am J Trop Med Hyg. 1998 May;58(5):645-9. doi: 10.4269/ajtmh.1998.58.645. Am J Trop Med Hyg. 1998. PMID: 9598455 Clinical Trial.
-
Toxicity in rhesus monkeys following administration of the 8-aminoquinoline 8-[(4-amino-l-methylbutyl)amino]- 5-(l-hexyloxy)-6-methoxy-4-methylquinoline (WR242511).J Med Toxicol. 2008 Sep;4(3):157-66. doi: 10.1007/BF03161194. J Med Toxicol. 2008. PMID: 18821488 Free PMC article.
-
Tafenoquine: First Global Approval.Drugs. 2018 Sep;78(14):1517-1523. doi: 10.1007/s40265-018-0979-2. Drugs. 2018. PMID: 30229442 Review.
Cited by
-
Pharmacokinetic Models of Tafenoquine: Insights for Optimal Malaria Treatment Strategies.Pharmaceutics. 2024 Aug 26;16(9):1124. doi: 10.3390/pharmaceutics16091124. Pharmaceutics. 2024. PMID: 39339162 Free PMC article. Review.
-
Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics.Antimicrob Agents Chemother. 2015 Jul;59(7):3864-9. doi: 10.1128/AAC.00343-15. Epub 2015 Apr 13. Antimicrob Agents Chemother. 2015. PMID: 25870069 Free PMC article.
-
Prophylaxis of Plasmodium falciparum infection in a human challenge model with WR 238605, a new 8-aminoquinoline antimalarial.Antimicrob Agents Chemother. 1998 May;42(5):1293-4. doi: 10.1128/AAC.42.5.1293. Antimicrob Agents Chemother. 1998. PMID: 9593172 Free PMC article. Clinical Trial.
-
Synthesis and evaluation of naphthyridine compounds as antimalarial agents.Bioorg Med Chem Lett. 2007 Nov 15;17(22):6101-6. doi: 10.1016/j.bmcl.2007.09.044. Epub 2007 Sep 15. Bioorg Med Chem Lett. 2007. PMID: 17900897 Free PMC article.
-
A 'bottom-up' approach for endo-PK/PD analysis.Biopharm Drug Dispos. 2006 Oct;27(7):313-27. doi: 10.1002/bdd.508. Biopharm Drug Dispos. 2006. PMID: 16892181 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources